CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Cash Flow Y/Y Annual
Standard Biotools Inc   (NASDAQ: LAB)
Other Ticker:  
 
 

LAB's Net Cash Flow Growth by Quarter and Year

Standard Biotools Inc 's Net Cash Flow results by quarter and year

Download as CSV




LAB Net Cash Flow (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -43.12 -27.95 21.11
3rd Quarter September -29.20 -59.16 -62.65 -14.16
2nd Quarter June 7.73 -17.24 28.64 44.38
1st Quarter March -15.35 265.67 32.13 1.53
FY   -36.82 146.15 -29.83 52.86

LABs Annual Net Cash Flow
Standard Biotools Inc 's Net Cash Flow in the fiscal year 2024 $ 116.32 millions
Standard Biotools Inc 's Net Cash Flow in the fiscal year 2023 $ -29.83 millions
Standard Biotools Inc 's Net Cash Flow in the fiscal year 2022 $ 0.00 millions
Standard Biotools Inc 's Net Cash Flow in the fiscal year 2021 $ -40.07 millions
Standard Biotools Inc 's Net Cash Flow in the fiscal year 2020 $ 45.80 millions




LAB Net Cash Flow third quarter 2025 Y/Y Growth Comment
Standard Biotools Inc in the third quarter 2025 recorded net cash outflow of $ -29.20 millions.

According to the results reported in the third quarter 2025, Standard Biotools Inc achieved the best Net Cash Flow growth in Laboratory Analytical Instruments industry. While Standard Biotools Inc ' s Net Cash Flow no change of 0% ranks overall at the positon no. 442 in the third quarter 2025.


LAB Net Cash Flow ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - -35.47 % -
1st Quarter March - 726.86 % 2000 % -
FY   - - - -

Financial Statements
Standard Biotools Inc 's third quarter 2025 Net Cash Flow $ -29.20 millions LAB's Income Statement
Standard Biotools Inc 's third quarter 2024 Net Cash Flow $ -59.16 millions Quarterly LAB's Income Statement


LAB Net Cash Flow (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - -10.86 % 2800.65 %
1st Quarter March - - 52.2 % -
FY (Year on Year)   - - - -


Go to LAB Cash flow Statement >> Back to LAB Growth rate Comparisons >>


Net Cash Flow third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #69
Overall #442

Net Cash Flow Y/Y Growth Statistics
High Average Low
738.64 % -52.12 % -291.9 %
(Sep 30 2024)   (Dec 31 2019)
Net Cash Flow third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #69
Overall #442
Net Cash Flow Y/Y Growth Statistics
High Average Low
738.64 % -52.12 % -291.9 %
(Sep 30 2024)   (Dec 31 2019)

Net Cash Flow by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Standard Biotools Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LAB's III. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of -29.20 millions by Standard Biotools Inc come out even worse considering the 7.73 millions a quarter before.

Within Laboratory Analytical Instruments industry Standard Biotools Inc achieved highest sequential Net Cash Flow growth. While Standard Biotools Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LAB's III. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of -29.20 millions by Standard Biotools Inc come out even worse considering the 7.73 millions a quarter before.

Within Laboratory Analytical Instruments industry Standard Biotools Inc achieved highest sequential Net Cash Flow growth. While Standard Biotools Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Standard Biotools Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Net Cash Flow 12 Months Ending $ -79.93 $ -109.90 $ -134.87 $ 146.14 $ 161.31
Y / Y Net Cash Flow Growth (TTM) - - - - 738.64 %
Year on Year Net Cash Flow Growth Overall Ranking # 109 # 312 # 321 # 257 # 546
Seqeuential Net Cash Flow Change (TTM) - - - -9.4 % 2.21 %
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 442 # 527 # 622 # 507 # 650


Cumulative Net Cash Flow growth Comment
Standard Biotools Inc realized trailing twelve months net cash outflow of $ -80 millions, in the Sep 30 2025, compare to Net Cash Flow of $ 161 millions a year ago.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 109, from total ranking in previous quarter at 312.

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 1
Healthcare Sector # 16
Overall # 109

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
738.64 %
 -52.12 %
-291.9 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 69
S&P 500 # 442
Cumulative Net Cash Flow growth Comment
Standard Biotools Inc realized trailing twelve months net cash outflow of $ -80 millions, in the Sep 30 2025, compare to Net Cash Flow of $ 161 millions a year ago.

Among companies within the Healthcare sector 15 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 109, from total ranking in previous quarter at 312.


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 1
Healthcare Sector # 16
Overall # 109

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
738.64 %
-52.12 %
-291.9 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 69
S&P 500 # 442




Other Net Cash Flow Growth
Laboratory Analytical Instruments Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
LAB's Net Cash Flow Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth




Companies with similar Net Cash Flow no change for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2025
Abbott Laboratories-1.93%$ -1.926 millions
The Beauty Health Company-3.23%$ -3.230 millions
Gilead Sciences Inc -3.40%$ -3.401 millions
Lifestance Health Group Inc -4.30%$ -4.295 millions
Nuo Therapeutics Inc -5.86%$ -5.860 millions
Resmed Inc -7.24%$ -7.235 millions
Elite Health Systems Inc -13.19%$ -13.190 millions
Ideaya Biosciences Inc -15.17%$ -15.169 millions
10x Genomics Inc -17.42%$ -17.417 millions
Kairos Pharma Ltd -18.66%$ -18.662 millions
Charles River Laboratories International inc -20.09%$ -20.094 millions
Actuate Therapeutics Inc -20.80%$ -20.799 millions
Sigyn Therapeutics Inc -23.42%$ -23.422 millions
United Health Products Inc -27.48%$ -27.480 millions
Strata Skin Sciences Inc-29.70%$ -29.702 millions
Kezar Life Sciences Inc -30.60%$ -30.599 millions
Globus Medical Inc -32.97%$ -32.975 millions
Sensus Healthcare Inc -36.11%$ -36.113 millions
Mountain Crest Acquisition Corp V-36.51%$ -36.512 millions
Quoin Pharmaceuticals Ltd -40.21%$ -40.206 millions
Teladoc Health Inc -41.11%$ -41.108 millions
Viridian Therapeutics Inc -42.33%$ -42.329 millions
Catalyst Pharmaceuticals Inc -44.34%$ -44.338 millions
Anaptysbio inc-45.28%$ -45.278 millions
Bioxytran Inc -46.31%$ -46.312 millions
Promis Neurosciences inc -47.00%$ -46.998 millions
Conmed Corporation-47.97%$ -47.968 millions
Ardent Health Inc -49.96%$ -49.958 millions
Zevra Therapeutics Inc -54.48%$ -54.483 millions
Viatris Inc -54.69%$ -54.690 millions


About Standard Biotools Inc Net Cash Flow Growth Rates (LAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Standard Biotools Inc (CIK 1162194).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-25-264695
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Standard Biotools Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.